NCT06094842View on ClinicalTrials.gov

Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer

PHASE1WithdrawnINTERVENTIONAL
0
Timeline

Start Date

April 15, 2025

Primary Completion Date

March 15, 2028

Study Completion Date

March 15, 2028

Conditions
Prostate CarcinomaProstate Small Cell Neuroendocrine CarcinomaStage III Prostate Cancer AJCC v8Stage IV Prostate Cancer AJCC v8
Interventions
DRUG

Bendamustine

Given IV

PROCEDURE

Biopsy

Undergo tissue biopsy

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Scan

Undergo bone scan

PROCEDURE

Bridge Therapy

Undergo bridging therapy

PROCEDURE

Computed Tomography

Undergo CT

DRUG

Cyclophosphamide

Given IV

PROCEDURE

Echocardiography

Undergo ECHO

DRUG

Fludarabine

Given IV

PROCEDURE

Leukapheresis

Undergo leukapheresis

PROCEDURE

Multigated Acquisition Scan

Undergo MUGA

BIOLOGICAL

T-cell Receptor-engineered T-cells

Given autologous L1CAM-specific CAR+EGFRt+ T cells IV

PROCEDURE

X-Ray Imaging

Undergo chest x-ray

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER

NCT06094842 - Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | Biotech Hunter | Biotech Hunter